Lifitegrast
Back to search| Scientific Name: | Lifitegrast |
| Brand Name: | Xiidra |
| Company Owner: | Not Available |
| Mechanism Of Action | Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1) , a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1) . ICAM-1 may be overexpressed in corneal and conjunctival tissues in dry eye disease. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell proliferation/activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines, inflammatory mediators, chemokines, TNF-α, and IL-1 in human peripheral blood mononuclear cells. |
| Description of the Drug: | Lifitegrast is a medication used to treat dry eye disease. |
| Protein Data Bank: | Not Available |
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB11611
